Subject to regulatory risks surrounding PBM rebates and drug pricing transparency.

Faces a major disruptive threat to its PBM business model from a government policy to move more prescription drugs to over-the-counter status, which would reduce prescription volume and fees.

Mentioned for using an AI system to deny claims in seconds, a practice described as a reputational and financial risk. Its PBM business (Express Scripts) is also under threat from more transparent models.

Specifically mentioned as an example of a health insurance giant in a system the host is very bearish on. The long-term future is seen as threatened by potential policy changes aimed at reducing healthcare costs, posing a significant risk to its business model.

Faces significant event risk and stock price volatility due to political uncertainty surrounding the Affordable Care Act (ACA) tax credits. An expiration could lead to a mass exodus of customers from the marketplace, hurting revenue.

Faces significant regulatory and business model risk due to widespread negative sentiment towards its Pharmacy Benefit Manager (PBM) division, as highlighted by criticism from pharmaceutical executives.

The company's business model, which relies on its PBM, is identified as being vulnerable to disruption from transparent pricing models and faces risk from potential regulatory changes targeting industry opacity.